2,826 reports of this reaction
2.2% of all LAMOTRIGINE EXTENDED RELEASE reports
#8 most reported adverse reaction
DIZZINESS is the #8 most commonly reported adverse reaction for LAMOTRIGINE EXTENDED RELEASE, manufactured by Advagen Pharma Limited. There are 2,826 FDA adverse event reports linking LAMOTRIGINE EXTENDED RELEASE to DIZZINESS. This represents approximately 2.2% of all 130,110 adverse event reports for this drug.
Patients taking LAMOTRIGINE EXTENDED RELEASE who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is a less commonly reported adverse event for LAMOTRIGINE EXTENDED RELEASE, but still significant enough to appear in the safety profile.
In addition to dizziness, the following adverse reactions have been reported for LAMOTRIGINE EXTENDED RELEASE:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 2,826 FDA reports for LAMOTRIGINE EXTENDED RELEASE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 2.2% of all adverse event reports for LAMOTRIGINE EXTENDED RELEASE, making it a notable side effect.
If you experience dizziness while taking LAMOTRIGINE EXTENDED RELEASE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.